Common use of Initial Grant Clause in Contracts

Initial Grant. COMPANY shall issue a total of [***] shares (the “Shares”) of Common Stock of COMPANY, $0.0001 par value per share (“Common Stock”), to M.I.T. and those individuals listed on Appendix C (the “M.I.T. Holders”), ▇▇▇▇▇▇▇ and ▇▇▇▇, in the amounts specified in Appendix C; provided, however, that each of M.I.T., ▇▇▇▇▇▇▇ and GIST and each M.I.T. Holder (collectively, the “Shareholders” and individually, each a “Shareholder”), shall execute (I) an investment letter in a form mutually agreeable to M.I.T. and COMPANY; and (II) a First Amendment to Right of First Refusal and Co-Sale Agreement in the form attached hereto as Exhibit C (the “ROFR and Co-Sale Agreement”). Such issuance shall be recorded on the Stock Transfer Ledger of COMPANY on the EFFECTIVE DATE and the Shares shall be delivered to each Shareholder within thirty (30) days after the EFFECTIVE DATE. COMPANY agrees that the joinder agreement that binds ▇▇▇▇▇▇▇ to the ROFR and Co-Sale Agreement shall provide that ▇▇▇▇▇▇▇ shall not be bound by Section 7 (Co-Sale) thereof.

Appears in 2 contracts

Sources: Exclusive Patent License Agreement (BIND Therapeutics, Inc), Exclusive Patent License Agreement (BIND Therapeutics, Inc)

Initial Grant. COMPANY shall issue a total of [***] shares (the “Shares”) of Common Stock of COMPANY, $0.0001 par value per share (“Common Stock”), to M.I.T. and those individuals listed on Appendix C persons as M.I.T. shall direct (the “M.I.T. Holders”), ▇▇▇▇▇▇▇, HARVARD, INSTITUTE and ▇▇▇▇CMCC, in the amounts specified in Appendix Cas M.I.T. shall direct, such information to be provided within thirty (30) days of the EFFECTIVE DATE; provided, however, that each of M.I.T., [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. ▇▇▇▇▇▇▇ and GIST ▇, HARVARD, INSTITUTE, CMCC and each M.I.T. Holder (collectively, the “Shareholders” and individually, each a “Shareholder”), shall execute (I) an investment letter in a form mutually agreeable to M.I.T. and COMPANY; and (II) a First Amendment to Right of First Refusal and Co-Sale Agreement in the form attached hereto as Exhibit C (the “ROFR and Co-Sale Agreement”). Such issuance shall be recorded on the Stock Transfer Ledger of COMPANY on the EFFECTIVE DATE and and, subject to the conditions in the proviso above, the Shares shall be delivered to each Shareholder within thirty (30) days after the EFFECTIVE DATE. COMPANY agrees that the joinder agreement that binds ▇▇▇▇▇▇▇ to the ROFR and Co-Sale Agreement shall provide that ▇▇▇▇▇▇▇ shall not be bound by Section 7 (Co-Sale) thereof.

Appears in 2 contracts

Sources: Exclusive Patent License Agreement (Selecta Biosciences Inc), Exclusive Patent License Agreement (Selecta Biosciences Inc)

Initial Grant. COMPANY shall issue a total of [***] 293,338 shares (the “Shares”) of Common Stock of COMPANY, $0.0001 par value per share (“Common Stock”), to M.I.T. and those individuals listed on Appendix C (the “M.I.T. Holders”), ▇▇▇▇▇▇▇ and ▇▇▇▇, in the amounts specified in Appendix C; provided, however, that each of M.I.T., ▇▇▇▇▇▇▇ and GIST and each M.I.T. Holder (collectively, the “Shareholders” and individually, each a “Shareholder”), shall execute (I) an investment letter in a form mutually agreeable to M.I.T. and COMPANY; and (II) a First Amendment to Right of First Refusal and Co-Sale Agreement in the form attached hereto as Exhibit C (the “ROFR and Co-Sale Agreement”). Such issuance shall be recorded on the Stock Transfer Ledger of COMPANY on the EFFECTIVE DATE and the Shares shall be delivered to each Shareholder within thirty (30) days after the EFFECTIVE DATE. COMPANY agrees that the joinder agreement that binds ▇▇▇▇▇▇▇ to the ROFR and Co-Sale Agreement shall provide that ▇▇▇▇▇▇▇ shall not be bound by Section 7 (Co-Sale) thereof.

Appears in 1 contract

Sources: Exclusive Patent License Agreement (BIND Therapeutics, Inc)